Dianthus Therapeutics Inc... (DNTH)
16.96
-0.90 (-5.04%)
At close: Apr 03, 2025, 3:59 PM
16.91
-0.31%
Pre-market: Apr 04, 2025, 04:10 AM EDT
-5.04% (1D)
| Bid | 15.97 |
| Market Cap | 545M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.55 |
| PE Ratio (ttm) | -6.65 |
| Forward PE | -6.46 |
| Analyst | Buy |
| Ask | 18.53 |
| Volume | 418,388 |
| Avg. Volume (20D) | 299,626 |
| Open | 16.32 |
| Previous Close | 17.86 |
| Day's Range | 15.89 - 17.42 |
| 52-Week Range | 15.89 - 32.27 |
| Beta | 1.63 |
About DNTH
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 201...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 78
Stock Exchange NASDAQ
Ticker Symbol DNTH
Website https://dianthustx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for DNTH stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 206.51% from the latest price.
Stock Forecasts9 months ago
+5.19%
Dianthus Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
9 months ago
+5.01%
Dianthus Therapeutics shares are trading higher after the company announced FDA. clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
